drugset / Trial / NCT00324038

Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly

NCT00324038

Phase 4 Completed 219 enrolled Napp Pharmaceuticals Limited
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective is to compare buprenorphine transdermal delivery system (BTDS) with standard- treatment in subjects with osteoarthritis (OA).

Timeline

Start
2006-03
Primary completion
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetaminophen Small molecule 500 mg Oral
Subject Buprenorphine Other / unclassified 5 mg Other
Subject Buprenorphine Other / unclassified 10 mg Other
Subject Buprenorphine Other / unclassified 20 mg Other
Comparator Codeine Small molecule 8 mg Oral
Comparator Codeine Small molecule 15 mg Oral
Comparator Codeine Small molecule 30 mg Oral

Indications